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Background: The Prognostic value of microvessel density in cancer remains unclear. Recent studies have
suggested that the uneven distribution of microvessels in tumours caused the variation in sample selection which
led to different prognostic outcome. The enhancement pattern of Contrast-enhanced computed tomography
(CECT) is determined in part by the microvessel distribution in solid tumors. Therefore, survival analysis of tumors
grouping by the enhancement pattern and the pattern of microvessel distribution is important.
Methods: Survival analysis grouped by the tumor enhancement pattern and the microvessel distribution was
carried out in 255 patients with invasive ductal carcinoma.
Results: There were significant differences in overall survival (OS) and disease-free survival (DFS) among the
homogeneous, heterogeneous and peripheral enhancement groups. There were significant differences between
OS and DFS groups with uniform and uneven distributions of microvessels.
Conclusions: The distribution of microvessels in a tumor is a potential prognostic indicator in patients with
breast cancer, and can be assessed by CECT prior the operation.Background
Angiogenesis is the formation of new blood vessels from
the endothelium of the existing vasculature. When a
new tumor reaches 1–2 mm in size, its growth requires
the induction of new blood vessels, which may lead to
the development of metastases via the penetration of
malignant cells into the blood circulation [1]. Microves-
sel density (MVD) assessment was once considered a
useful indicator in the selection of those node-negative
patients with breast carcinoma who are at high risk to
have occult metastasis at presentation [2], and was also an
commonly used important technique to quantify angio-
genesis in other solid tumours [3]. However, its prognostic
value remains unclear. The majority of published studies
have shown a positive correlation between intratumoral
MVD and prognosis in solid tumours [4], but not all stud-
ies have demonstrated such association, and this may be
attributed to the significant differences in sample col-
lection, immunostaining techniques, vessel counting and* Correspondence: sjbreast@sina.com
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reproduction in any medium, provided the orstatistical analysis, although a number of biological differ-
ences may also account for the discrepancy [5]. Recently,
it has been accepted that the discrepancy is due to the un-
differentiated vessel density caused by variation of sample
selection [6], and some researchers even began to apply
computing analysis to quantify vascular properties per-
taining to size, shape and spatial distributions in photo-
graphed fields of CD34 stained sections [7]. Contrast-
enhanced computed tomography (CECT)-based criteria
improve the diagnostic accuracy of sentinel lymph node
metastases and are useful for evaluating the axillary status
in patients with early-stage breast cancer [8]. The en-
hancement pattern of computed tomography (CT) is de-
termined in part by the distribution of microvessels in
solid tumours [9]. Therefore, it is important to carry out
survival analysis grouping by the enhancement pattern
and the pattern of microvessel distribution.
Methods
Study population
Between January 2008 and December 2011, a total of
259 patients with invasive ductal carcinoma (IDC) werehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Hospital of China Medical University, Shenyang, China. In-
clusion criteria for the study are: (1) no prior history of
breast cancer or other malignancies, (2) no history of neoad-
juvant therapy; (3) not pregnant at the time of diagnosis. All
patients provided written consent for the contrast-enhanced
computed tomography (CECT) scan, and agreed to undergo
mammary tomography with enhancement pattern. The cen-
ter and the edge of each breast cancer sample was stored in
a cryogenic refrigerator (-86°C). All patients were treated
with postoperational systemic adjuvant therapy (chemother-
apy, radiotherapy, and endocrine therapy) guided by
the National Comprehensive Cancer Network (NCCN).
Follow-up examination was carried out at 4-month inter-
vals during the first 2 years, at 6-month intervals during
the next 3 years, and at 12-month intervals thereafter until
December 2012. The diagnosis of local recurrence and
contralateral breast cancer was supported by biopsy, and
distant metastasis was diagnosed by more than two types
of imaging examinations. DFS was defined as the time
period from the first day after surgery to the first local re-
currence or distant metastasis. OS was measured from the
first day of follow-up. In this patient group, we collected
anthropometric data (age at diagnosis, history of meno-
pause, family history, surgery, chemotherapy, radiological
therapy, target therapy and hormonal therapy), as well
as variables related to the tumor – size, location, TNM
staging, histological grade, lymphovascular invasion, meta-
static nodes, estrogen receptor (ER), progesterone recep-
tor (PgR), Ki67, P53, and microvessel density at the center
and edge of tumor. Pathological tumor stage was assessed
according to the criteria established by the 6th edition of
the American Joint Committee on Cancer (AJCC) staging
manual. The histological grade of the tumors was classi-
fied into grades I–III according to the Nottingham com-
bined histological grade. All patients signed the Informed
Consent and the study was approved by the Ethics Com-
mittee of Shengjing Hospital.
Immunohistochemistry and fluorescence in situ
hybridization
Immunohistochemistry (IHC) was performed on formalin-
fixed, paraffin-embedded samples obtained from the path-
ology registry. Tissue sections (5-μm) were deparaffinized
in xylene and rehydrated in a graded series of ethanol.
Slides were treated with methanol containing 0.3% hydro-
gen peroxide to block any endogenous peroxidase activity.
Heat-mediated antigen retrieval with the pressure cooker
method was used for all staining except for the epidermal
growth factor receptor (EGFR), which did not need re-
trieval. Antibodies recognizing the ER, PgR, and HER2
were used for immunohistochemical studies on serial tis-
sue sections from each case; EGFR and Ki67 antibodies
were used in luminal A tumours. Five markers wereassessed: ER, PgR, HER2, and EGFR, which were used
for breast carcinoma subtypes, and Ki67, which was
used to divide luminal A tumors into two groups. The
primary antibodies used in this study include ER (SP1,
1:200 dilution; ZETA), PgR (SP2, 1:200 dilution; ZETA),
HER2 (CB11, 1:100 dilution; Invitrogen, Carlsbad, CA,
USA), EGFR (SP9, 1:100 dilution; Invitrogen), Ki67 (K-2,
1:100 dilution; Invitrogen) and antiCD34 (class II, clone
QBEnd 10, Dako-Cytomation, Glostrup, Denmark, di-
lution 1:50). Immunostaining was scored in a double-
blinded manner by two different pathologists who were
blinded to the clinicopathologic characteristics and out-
come of each patient. For each antibody, the location of
immunoreactivity, percentage of stained cells, and inten-
sity were determined. The evaluation of protein expres-
sion was determined as mean ± SEM from each individual
case. ER and PgR staining was assessed by Allred scoring,
with positive scores ranging from 2 to 8 [10]. EGFR
staining was considered positive if any cytoplasmic and/or
membrane staining was observed. HER + (IHC) was de-
fined as strong whole membrane staining in >30% of the
tumor cells, and Ki67 status was expressed in terms of
percentage of positive cells, with a threshold of 14% of
positive cells [11]. Fluorescence in situ hybridization
(FISH) analysis was performed on IHC + tumours using
the PathVysion HER2 DNA Probe Kit (Vysis, Downers
Grove, IL, USA). HER2-positive staining was defined as
FISH-positive, and HER2-negative staining was defined as
IHC 0 or negative FISH results.
Clinicopathological subtypes
The clinical pathological subtypes of breast cancer were
described, and were best matched with gene expression
patterns [12]. Briefly, the subtype definitions are as fol-
lows: luminal A (ER + and/or PgR + and HER2- and/or
Ki67 < 14%), luminal B (ER + and/or PgR + and HER2+
and/or Ki67 ≥ 14%), HER2 overexpression (ER-, PgR-,
and HEr2+), triple-negative (ER-, PgR-, HER2-).
Contrast-enhanced computed tomography and tumor
enhancement patterns
All CECT examinations were performed on a 64-detector
row scanner (Siemens, Germany, Definition 2008 G H-SP),
with the patients lying in prone position and with both
arms spread out from the body. Bilateral whole breast
scanning was performed within a single breath-hold with
1-mm detector raw collimation for breast cancer screening.
The technical parameters were standardized as follows:
120 kV, 36 mA and 3-mm-thick contiguous section. CT
images from the lower edge of breast to neck were ob-
tained, for which 80 mL of non-ionic contrast material
(Omnipaque 350, Cork, Ireland) was injected intravenously
at a flow rate of 2.5 mL/s. Postcontrast CECT scanning
was initiated 30 s after the start of contrast. The delay
Figure 1 Distribution of microvessels. A. CECT images. B. Immunohistochemical images.
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trast enhancement was 60 s for early-phase imaging and
90 s for late-phase imaging. Most of the breast malignant
tumor in the CECT performance had tissue fortified; only
a few were not strengthened. According to CECT imaging
performance morphology, the enhanced patterns of the
breast tumours were classified by into peripheral enhance-
ment, heterogeneous enhancement, homogeneous enhance-
ment and centric enhancement [Figure 1A]. PeripheralFigure 2 Diagram of tumor partition. Illustration: It was the main aim to
the tumor and the normal breast tissue.enhancement is similar to ring strengthening, in which
mainly the surrounding area of neoplasm is fortified.
The CT value difference between the surrounding area
and the central area is more than 10 Hounsfield units
(HU). Heterogeneous enhancement means that there is
an obvious difference of reinforcement in the various
areas of the tissue, and the CT value difference is more
than 10 HU. Homogeneous enhancement means that
there is no obvious difference in reinforcement in thelay the chest flat so that the edge of tumor must be located between




Ki67+ (n = 52)
Luminal B
HER2 + (22)
HER2 overexpression (16) TNBC (46) Statistics P
Age (years) 51.67 ± 10.10 50.88 ± 8.16 55.41 ± 8.98 52.13 ± 6.49 51.91 ± 10.90 0.896 0.467
Menopause 2.378 0.667
Postmenopausal 56 24 14 7 22
Premenopausal 63 28 8 9 24
Family history 2.075 0.722
No 109 49 21 16 42
Yes 10 3 1 0 4
Diameter 2.15 ± 0.98 2.32 ± 0.94 2.43 ± 1.07 3.09 ± 1.49 2.50 ± 1.18 3.292 0.012
Quadrant 16.851 0.395
Areolar 3 1 0 0 1
Inner upper 28 8 0 2 7
Inner lower 14 5 1 2 3
Outer lower 21 11 3 2 6
Outer upper 53 27 18 10 29
Enhancement patterns 59.901 0.000
Homogeneous 40(33.6%) 18(34.6%) 7(31.8%) 5(31.3%) 12(26.1%)
Heterogeneous 71(59.7%) 29(55.8%) 8(36.4%) 3(18.8%) 10(21.7%)
Peripherals 8(6.7%) 5(9.6%) 7(31.8%) 8(50.0%) 24(52.2%)
Difference of MVD (Edge - Center) 3.12 ± 6.26 3.18 ± 7.95 7.61 ± 8.53 7.98 ± 8.97 10.23 ± 8.72 9.543 0.000
Grade of DMVD 42.300 0.000
Uniform distribution 102(85.7%) 44(84.6%) 14(63.6%) 6(37.5%) 21(45.7%)
Uneven distribution 17(14.3%) 8(15.4%) 8(36.4%) 10(62.5%) 25(54.3%)
Histological grade 30.927 0.000
I 37(31.1%) 16(30.8%) 0(0%) 1(6.3%) 9(19.6%)
II 77(64.7%) 29(55.8%) 16(72.7%) 10(62.5%) 34(73.9%)
III 5(4.2%) 7(13.5%) 6(27.3%) 5(31.3%) 3(6.5%)
Cancer thrombosis 7.806 0.099
Negative 89 41 11 10 34
Positive 30 11 11 6 12
Nodal metastasis 6.825 0.145
Negative 60 24 8 3 23
Positive 59 28 14 13 23
Number of metastatic nodes 2.09 ± 4.16 2.94 ± 5.01 6.77 ± 9.63 11.88 ± 11.37 4.89 ± 9.70 9.167 0.000
Clinical stage 50.721 0.000
I 33(27.7%) 15(28.8%) 1(4.5%) 0(0%) 10(21.7%)
IIA 38(31.9%) 11(21.2%) 10(45.5%) 4(25.0%) 13(28.3%)
IIB 39(32.8%) 21(40.4%) 4(18.2%) 4(25.0%) 16(34.8%)
IIIA 7(5.9%) 3(5.8%) 3(13.6%) 3(18.8%) 2(4.3%)
IIIB 1(0.8%) 2(3.8%) 2(9.1%) 1(6.3%) 1(2.2%)
IIIC 1(0.8%) 0(0%) 2(9.1%) 4(25%) 4(8.7%)
IV 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
P53 (%) 27.76 ± 30.19 32.65 ± 34.17 41.55 ± 30.32 30.19 ± 32.23 35.50 ± 35.33 1.141 0.338
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Table 1 Patient characteristics and survival analysis (by clinicopathological subtype) (Continued)
Operation 5.455 0.244
Mastectomy 102 47 21 16 43
Tumorectomy 17 5 1 0 3
Chemotherapy program 49.253 0.002
Not performed 1(0.8%) 0(0%) 0(0%) 0(0%) 1(2.2%)
CMF 2(1.7%) 0(0%) 0(0%) 0(0%) 0(0%)
CAF or AC 42(35.3%) 17(32.7%) 2(9.1%) 0(0%) 11(23.9%)
CEF or EC 21(17.6%) 12(23.1%) 10(45.5%) 5(31.3%) 14(30.4%)
T or TC or TP 42(35.3%) 15(28.8%) 4(18.2%) 2(12.5%) 13(28.3%)
TAC or A-T 10(8.4%) 8(15.4%) 6(27.3%) 9(56.3%) 7(15.2%)
Radiotherapy 6.682 0.154
Not performed 67 27 10 4 27
Performed 52 25 12 12 19
Endocrine therapy 262.436 0.000
Not performed 0(0%) 0(0%) 0(0%) 16(100%) 46(100%)
TAM 75(63.0%) 32(61.5%) 12(54.5%) 0(0%) 0(0%)
LHRH 11(9.2%) 7(13.5%) 0(0%) 0(0%) 0(0%)
AI 33(27.7%) 13(25.0%) 10(45.5%) 0(0%) 0(0%)
Targeted therapy 33.619 0.000
Not performed 119(100%) 52(100%) 20(90.9%) 13(81.3%) 46(100%)
Performed 0(0%) 0(0%) 2(9.1%) 3(18.8%) 0(0%)
Overall survival 99.2% 98.1% 86.4% 87.5% 91.3% 17.629 0.024
Event 1 1 3 2 4
Deaths 1 1 3 2 3
Lost to follow-up 0 0 0 0 1
Median survival time 54.0 48.0 36.0 29.4 35.2 31.845 0.000
Disease-free survival 98.3% 94.3% 72.7% 75.0% 82.6% 56.588 0.001
Event 2 3 6 4 7
Local recurrence 0 1 0 0 0
Contralateral breast cancer 1 1 2 0 0
Lung metastasis 0 0 0 1 1
Hepatic metastasis 0 0 2 1 2
Brain metastasis 0 0 0 1 2
Multi-organ 1 1 2 1 2
Lost to Follow-up 0 0 0 0 1
Disease-free survival 54.0 48.0 35.4 22.5 31.7 59.248 0.000
Follow-up time 4.741 0.001
Median 23.0 25.5 30.5 17.0 20.0
Range 12-59 12-49 12-38 12-25 12-53
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is less than 10 HU. In centric enhancement, mainly the
central area of the neoplasm is reinforced and the CT value
difference between the central area and the surrounding
area is more than 10 HU. Four patients failed to enter the
study for the purpose of statistical relevance, including threepatients without tumor strengthened image and one patient
with centric enhancement, therefore 255 patients were
ultimately enrolled in this study based on the classification
of peripheral, heterogeneous and homogeneous enhance-
ment. All patients signed the Informed Consent for contrast
medium hypersensitivity and the radiation dose was 9 Smv.
Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 The survival analysis and cox proportional hazards model. A. Analysis grouping by the Clinicopathological Subtypes. B. Cox proportional
hazards model and Analysis grouping by the Patterns of Tumor Enhancement. Cox proportional hazards model of biological factors (including tumor
enhancement mode under CT). C. Cox proportional hazards model and Analysis grouping by the Distribution of MVD. Cox proportional hazards model of
biological factors (including difference of MVD).
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density
The largest section of the tumor, which was parallel to
the chest wall and more than 3 mm thick, was obtained
by open surgery. The center and edge of the tumor were
determined by naked eye, and the weight of each speci-
men was more than 30 mg [Figure 2]. All samples were
stored in the freezer (-86°C) after quick-freezing in li-
quid nitrogen. MVD was evaluated by immunohisto-
chemical staining of tumor vessels for CD34 in whole
tissue sections. Any immunopositive single cell or clus-
ter of cells, clearly separated from adjacent clusters and
from the background, with or without a lumen, was con-
sidered to be an individual vessel. Microvessels in the
five most vascularized areas in a 200× magnification field
(0.74 mm2) were counted simultaneously by two ob-
servers, and the average value of the five fields was calcu-
lated. The difference in MVD (DMVD) of each sample was
the discrepancy from the average MVD at the edge minus
that at the center of the tumor. If the discrepancy was less
than 10 microvessels, the distribution of MVD was consid-
ered uniform; if the discrepancy was greater than or equal
to 10, the distribution was considered uneven [Figure 1B].
Statistics
All statistical analyses were carried out using SPSS soft-
ware (version 17.0 for Windows). Grouping criteria in-
clude clinicopathological subtypes, patterns of tumor
enhancement, and distribution of MVD. The correlation
analyses among various groups and the various bio-
logical factors were examined by the X2 test or ANVOA
analysis. For the survival analysis, Kaplan–Meier curves
were constructed for overall survival (OS) and disease-free
survival (DFS). The log-rank test was used to compare
survival differences among the groups. Cox proportional
hazards models were used to calculate relative risk ac-
counting for covariates. P values less than 0.05 were con-
sidered statistically significant.
Results
Survival analysis grouping by clinicopathological subtype
One hundred and nineteen patients were classified as lu-
minal A, 52 patients as luminal B with positive Ki67, 22
patients as luminal B with HER2 over-expression, 16 pa-
tients as HER2 over-expression, and 46 as triple- nega-
tive breast cancer. The characteristics of the 5 groups
are listed in Table 1. There were significant differences
in tumor diameter, patterns of tumor enhancement,DMVD (edge-center), grade of DMVD, histological grades,
number of metastatic nodes, clinical stage, chemother-
apy program, and in targeted therapy among the groups
(P < 0.05) [Table 1]. With a follow-up period of 12 to
59 months, the actual OS of luminal A, luminal B with
positive Ki67, luminal B with HER2 over-expression, of
HER2 over-expression, and of TNBC groups was 99.2%,
98.1%, 86.4%, 87.5%, and 91.3%, respectively, and there
was significant difference among the groups (P = 0.024)
[Table 1]. The median survival time of patients with lu-
minal A, luminal B with positive Ki67, luminal B with
HER2 over-expression, HER2 over-expression, and TNBC
was 54, 48, 36, 29.4, and 35.2 months, respectively, and
there was a significant difference among the groups (P =
0.000) [Table 1]. The actual DFS of luminal A, luminal B
with positive Ki67, luminal B with HER2 over-expression,
HER2 over-expression, and TNBC groups was 98.3%,
94.3%, 72.7%, 75.0%, and 82.6%, respectively, and there
was a significant difference among the groups (P = 0.001)
[Table 1]. The median DFS time of luminal A, luminal B
with positive Ki67, luminal B with HER2 over-expression,
HER2 over-expression, and TNBC groups was 54, 48, 35.4,
22.5, and 31.7 months, respectively, and there was a signifi-
cant difference among the groups (P = 0.000) [Table 1]. At
the same time, significant differences were observed
among the curves for OS and DSF (P = 0.000; P = 0.000)
[Figure 3A].
Cox proportional hazards model (including CT tumor
enhancement patterns)
Fourteen independent biological factors were used to
build a COX proportional hazard model for death and
tumor progression, including the age, history of meno-
pause, family history, tumor diameter, quadrant, patterns
of CT enhancement, histological grade, cancer throm-
bosis, lymph node metastasis, and tumor markers. There
were significant differences in the patterns of tumor en-
hancement, lymph node metastasis, and HER2 between
death (P < 0.05) and Exp (B) (expose of the B coefficient),
namely 4.555, 9.384 and 4.091, respectively. There were
significant differences in the tumor diameter, patterns of
tumor enhancement, lymph node metastasis, and HER2
between tumor progression (P < 0.05) and Exp (B), namely
1.596, 10.311, 4.542 and 2.910, respectively [Figure 3B].
Survival analysis grouping by tumor enhancement patterns
Eighty-two patients were classified as homogeneous en-
hancement, 121 patients as heterogeneous enhancement,








Age(years) 51.35 ± 8.51 52.24 ± 10.37 52.00 ± 9.53 0.210 0.811
Menopause 1.388 0.499
Postmenopausal 41 54 28
Premenopausal 41 67 24
Family history 1.095 0.579
No 76 111 50
Yes 6 10 2
Diameter 2.08 ± 0.91 2.31 ± 1.04 2.78 ± 1.28 7.028 0.001
Quadrant 12.629 0.125
Areolar 2 1 2
Inner upper 13 29 3
Inner lower 11 9 5
Outer lower 13 22 8
Outer upper 43 60 34
Difference of MVD
(Edge - Center)
-0.42 ± 5.72 3.73 ± 4.67 17.02 ± 3.88 211.273 0.000
Grade of DMVD 179.854 0.000
Uniform distribution 77(93.9%) 110(90.9%) 0(0%)
Uneven distribution 5(6.1%) 11(9.1%) 52(100%)
Histological grade 2.021 0.732
I 22 31 10
II 51 80 35
III 9 10 7
Cancer thrombosis 2.910 0.233
Negative 60 92 33
Positive 22 29 19
Nodal metastasis 1.588 0.452
Negative 25 61 22
Positive 47 60 30
Number of metastatic nodes 3.80 ± 6.88 2.51 ± 5.30 6.73 ± 10.17 6.540 0.002
Clinical stage 19.007 0.040
I 20(24.4%) 32(26.4%) 7(13.5%)
IIA 25(30.5%) 37(30.6%) 14(26.9%)
IIB 29(35.4%) 38(31.4%) 17(32.7%)
IIIA 4(4.9%) 10(8.3%) 4(7.7%)
IIIB 2(2.4%) 2(1.7%) 3(5.8%)
IIIC 2(2.4%) 2(1.7%) 7(13.5%)
IV 0(0%) 0(0%) 0(0%)
ER 31.203 0.000
Negative 29(35.4%) 32(26.4%) 37(71.2%)
Positive 53(64.6%) 89(73.6%) 15(28.8%)
PgR 34.485 0.000
Negative 24(29.3%) 29(24.0%) 36(69.2%)
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Table 2 Characteristics of patients and survival analysis (by the patterns of tumor enhancement) (Continued)
Positive 58(70.7%) 92(76.0%) 16(30.8%)
HER2 11.200 0.004
Negative 70(85.4%) 110(90.9%) 37(71.2%)
Positive 12(14.6%) 11(9.1%) 15(28.8%)
Ki67 14.736 0.001
Negative (<14%= 53(64.6%) 77(63.6%) 18(34.6%)
Positive (>14%) 29(35.4%) 44(36.4%) 34(65.4%)
P53 (%) 33.98 ± 32.59 30.35 ± 31.32 30.27 ± 33.83 0.357 0.700
Clinicopathological subtypes 59.901 0.000
Luminal A 40(48.8%) 71(58.7%) 8(15.4%)
Luminal B (Ki67+) 18(22.0%) 29(24.0%) 5(9.6%)
Luminal B (HER2+) 7(8.5%) 8(6.6%) 7(13.5%)
HER2 overexpression 5(6.1%) 3(2.5%) 8(15.4%)
TNBC 12(14.6%) 10(8.3%) 24(46.2%)
Operation 4.885 0.087
Mastectomy 72 106 51
Tumorectomy 10 15 1
Chemotherapy program 14.344 0.279
Not performed 0 1 1
CMF 1 1 0
CAF or AC 23 42 7
CEF or EC 19 27 16
T or TC or TP 27 34 15
TAC or A-T 12 16 13
Radiotherapy 1.560 0.458
Not performed 40 69 26
Performed 42 52 26
Endocrine therapy 53.381 0.000
Not performed 17(20.7%) 13(10.7%) 32(61.5%)
TAM 38(46.3%) 68(56.2%) 13(25.0%)
LHRH 7(8.5%) 8(6.6%) 3(5.8%)
AI 20(24.4%) 32(26.4%) 4(7.7%)
Targeted therapy 2.329 0.312
Not performed 79 119 52
Performed 3 2 0
Overall survival 100% 95.9% 88.5% 11.876 0.018
Event 0 5 6
Deaths 0 5 5
Lost to follow-up 0 0 1
Median survival time 54.0 54.0 42.0 8.525 0.014
Disease-free survival 100% 95.9% 65.4% 63.908 0.000
Event 0 5 18
Local recurrence 0 0 1
Contralateral breast cancer 0 0 4
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Table 2 Characteristics of patients and survival analysis (by the patterns of tumor enhancement) (Continued)
Lung metastasis 0 0 2
Hepatic metastasis 0 0 5
Brain metastasis 0 1 2
Multi-organ 0 4 3
Lost to follow-up 0 0 1
Disease-free survival 54.0 54.0 29.5 45.952 0.000
Follow-up time 2.967 0.053
Median 21.0 25.0 21.0
Range 12-56 12-59 12-44
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of the groups are listed in Table 2; there were significant
differences in tumor diameter, DMVD (edge-center), grade
of DMVD, number of metastatic nodes, clinical stage, ER,
PgR, Her2, Ki67, clinicopathological subtypes, and endo-
crine therapy among the groups (P < 0.05) [Table 2]. With a
follow-up period of 12 to 59 months, the actual OS of the
homogeneous enhancement, heterogeneous enhancement,
and peripheral enhancement groups was 100%, 95.9%, and
88.5%, respectively, and there was a significant difference
among the groups (P = 0.018) [Table 2]. The median sur-
vival time of the homogeneous enhancement, heteroge-
neous enhancement, and peripheral enhancement groups
was 54, 54, and 42 months, respectively, and there was a sig-
nificant difference among the groups (P = 0.014) [Table 2].
The actual DFS of the homogeneous enhancement, hetero-
geneous enhancement, and peripheral enhancement groups
was 100%, 95.9%, and 65.4%, respectively, and there was a
significant difference among the groups (P = 0.000) [Table 2].
The median DFS time of the homogeneous enhancement,
heterogeneous enhancement, and peripheral enhancement
groups was 54, 54, and 29.5 months, respectively, and there
was a significant difference among the groups (P = 0.000)
[Table 2]. At the same time, significant differences were ob-
served among groups in the curves for OS and DFS (P =
0.001; P = 0.000) [Figure 3B].
Cox proportional hazards model (including MVD
distribution)
Fourteen independent biological factors were used to
build a COX proportional hazard model for death and
tumor progression, including age, history of menopause,
family history, tumor diameter, quadrant, grade of DMVD,
histological grade, cancer thrombosis, lymph node metas-
tasis, and tumor markers. There were significant differ-
ences in the grade of DMVD and lymph node metastasis
between death (P < 0.05) and Exp (B) (expose of the B co-
efficient), namely 62.369 and 19.393, respectively. There
were significant differences in age, grade of DMVD, lymph
node metastasis, and Ki67 between tumor progression(P < 0.05) and Exp (B), namely 0.905, 112.292, 4.827
and 4.180, respectively [Figure 3C].
Survival analysis grouping by grade of DMVD
Distribution was classified as uniform in 187 patients
and as uneven in 68 patients. The characteristics of the
two groups are listed in Table 3. There were significant
differences between groups in tumor diameter, patterns
of tumor enhancement, DMVD (edge-center), number
of metastatic nodes, clinical stage, ER, PgR, Her2, Ki67,
clinicopathological subtypes, chemotherapy, and endo-
crine therapy (P < 0.05) [Table 3]. With a follow-up period
of 12 to 59 months, the OS of the uniform distribution
group was significantly longer than in the uneven distribu-
tion group (99.5% vs. 85.3%, P = 0.000) [Table 3]. The me-
dian survival time of both groups was 54 months, but
there was a significant difference between the groups (P =
0.000) [Table 3]. The DFS of the uniform distribution group
was significantly longer than that in the uneven distribution
group (99.5% vs. 67.6%, P = 0.000) [Table 3]. The median
DFS was significantly longer in the uniform distribution
group than that in the uneven distribution group (54 vs.
31.9 months, P = 0.000) [Table 3]. At the same time,
significant differences were observed between groups
in the curves for OS and DFS (P = 0.000; P = 0.000)
[Figure 3C].
Discussion
According to a recent report from Morocco, TNBC, par-
ticularly the basal-like subgroup, has the poorest prog-
nosis among the clinicopathological subtypes [13]. The
HER2 over-expression subtype has an equally poor prog-
nosis among Chinese women [14,15]. The results of our
study show that only 18.8% of patients with the HER2
over-expression subtype and only 9.1% of patients with
luminal B (HER over-expression) subtype received tar-
geted therapy. Therefore, the curves for OS and DFS in
the patients with HER2 over-expression (luminal B HER2+
and HER2 OE) were similar to those of the TNBC group
and lower than those of other groups (luminal A and
Table 3 Characteristics of patients and survival analysis (by grade of DMVD)
Characteristic Uniform distribution (DMVD< 10) (n = 187) Uneven distribution (DMVD > 10) (68) Statistics P




Family history 0.012 1.000
No 174 63
Yes 13 5
Diameter 2.21 ± 0.95 2.67 ± 1.31 -3.061 0.002
Quadrant 5.680 0.224
Areolar 3 2
Inner upper 39 6
Inner lower 17 8
Outer lower 32 11
Outer upper 96 41




Difference of MVD (Edge - Center) 1.29 ± 5.03 15.60 ± 4.27 -20.873 0.000




Cancer thrombosis 1.891 0.204
Negative 140 45
Positive 47 23
Nodal metastasis 0.174 0.777
Negative 88 30
Positive 99 38
Number of metastatic nodes 2.91 ± 5.97 6.21 ± 9.42 -3.302 0.001
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Negative (<14%) 120(64.2%) 28(41.2%)
Positive (>14%) 67(35.8%) 40(58.8%)
P53 (%) 32.08 ± 31.58 29.90 ± 33.94 0.479 0.633
Clinicopathological subtypes 42.300 0.000
Luminal A 102(54.5%) 17(25.0%)
Luminal B (Ki67+) 44(23.5%) 8(11.8%)
Luminal B (HER2+) 14(7.5%) 8(11.8%)





Chemotherapy program 17.357 0.004
Not performed 0(0%) 2(2.9%)
CMF 2(1.1%) 0(0%)
CAF or AC 60(32.1%) 12(17.6%)
CEF or EC 43(23.0%) 19(27.9%)
T or TC or TP 59(31.6%) 17(25.0%)
TAC or A-T 23(12.3%) 18(26.5%)
Radiotherapy 2.012 0.160
Not performed 104 31
Performed 83 37
Endocrine therapy 38.443 0.000




Targeted therapy 0.116 1.000
Not performed 183 67
Performed 4 1
Overall survival 99.5% 85.3% 24.308 0.000
Event 1 10
Deaths 1 9
Lost to Follow-up 0 1
Median survival time 54.0 54.0 14.885 0.000
Disease-free survival 99.5% 67.6% 62.030 0.000
Event 1 22
Local recurrence 0 1
Contralateral breast cancer 0 4
Li et al. BMC Cancer 2014, 14:672 Page 12 of 14
http://www.biomedcentral.com/1471-2407/14/672
Table 3 Characteristics of patients and survival analysis (by grade of DMVD) (Continued)
Lung metastasis 0 2
Hepatic metastasis 0 5
Brain metastasis 0 3
Multi-organ 1 6
Lost to Follow-up 0 1
Disease-free survival 54.0 31.9 47.546 0.000
Follow-up time 0.384 0.701
Median 23.0 22.0
Range 12-58 12-59
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enhancement, lymph node metastasis and HER2 are
significant relative risk factors for death and tumor
progression.
CECT remains a cost-effective means to assess the sta-
tus of axillary lymph nodes among patients with breast
cancer despite the progress of positron emission tomog-
raphy/computed tomography (PET/CT) and magnetic
resonance imaging (MRI) [16,17]. Beginning in January
2008, most surgeons in our institution gradually adopted
preoperative CECT for assessment of axillary lymph nodes.
However, a recent study suggests that tumor vascularity is
a potential predictor of treatment outcomes in metastatic
renal cell carcinoma, and that CECT is correlated signifi-
cantly with microvessel density [18]. In our study, if the
pattern of tumor enhancement was replaced by the grade
of DMVD in the Cox model, the grade of DMVD and
lymph node metastasis were significant relative risk factors
for death, and age, grade of DMVD, lymph node metastasis
and Ki67 were significant relative risk factors for tumor
progression.
We carried out survival analysis according to the pat-
terns of tumor enhancement, and found that the tumors
with peripheral enhancement had the poorest prognosis
and tumors with homogeneous enhancement had the
best prognosis. We then conducted survival analysis ac-
cording to the distribution of MVD, and found that tu-
mours with blood vessels concentrating on the edge had
the poorest prognosis compared to other tumours. There-
fore, our findings suggest that the distribution of micro-
vessels in breast cancer may determine the prognosis.
About a decade ago, Linder et al. demonstrated that
angiogenesis in pancreatic tumours was not uniform, and
that the tumor cells with more microvessels had greater
proliferation capacity than those with fewer microvessels
[19]. The uneven distribution of MVD is most likely the
reasonable explanation for the differences in the prognos-
tic value of MVD reported in different studies [20-22].
According to the theory of evolution, proliferation, anti-
apoptosis/immortalization, angiogenesis, and metastasis
are the “survival instinct” of the cancer cell when underthe threat of hypoxia [23]. Angiogenesis is the key mech-
anism for cancer cell invasion and metastasis [24,25].
There are many proteins participating in angiogenesis,
such as hypoxia-inducing factor and vascular endothelial
growth factor [26]. The results of our previous study also
suggest that miR-20a and miR-20b are differentially dis-
tributed in breast cancer, while VEGF-A and HIF-1alpha
mRNA have coincident distributions, and VEGF-A and
HIF-1alpha proteins have uneven and opposing distri-
butions to the miRNAs [27]. To date, we have only dis-
covered the tip of the iceberg with regard to the
mechanism of heterogeneity in tumor angiogenesis. How-
ever, we are confident that the distribution of microvessels
in a tumor is a useful indicator for prognosis among
the breast cancer patients, and can be assessed pre-
operationally by CECT.
Conclusions
The distribution of microvessels in a tumor is a potential
prognostic indicator in patients with breast cancer, and
can be assessed by preoperative by CECT.
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